Collegium Pharmaceutical, Inc. (COLL) Revenue History
Annual and quarterly revenue from 2013 to present
COLL Revenue Over Time (2013–2025)
COLL Revenue Growth History
8 of 9 years with positive growth- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- +1564.3%
- FY2018 revenue growth
- +884.7%
- FY2019 revenue growth
- +5.8%
- FY2020 revenue growth
- +4.5%
- FY2021 revenue growth
- -10.7%
- FY2022 revenue growth
- +67.6%
- FY2023 revenue growth
- +22.2%
- FY2024 revenue growth
- +11.4%
- FY2025 revenue growth
- +23.6%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $193.5M | +8.9% |
| Q4 2025 | $205.4M | +12.9% |
| Q3 2025 | $209.4M | +31.4% |
| Q2 2025 | $188.0M | +29.4% |
| Q1 2025 | $177.8M | +22.7% |
| Q4 2024 | $181.9M | +21.5% |
| Q3 2024 | $159.3M | +16.5% |
| Q2 2024 | $145.3M | +7.2% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
COLL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
COLL Revenue Analysis (2013–2025)
Current Revenue & Growth
As of June 22, 2026, Collegium Pharmaceutical, Inc. (COLL) generated trailing twelve-month (TTM) revenue of $796.3 million, reflecting solid growth of +8.9% year-over-year. The most recent quarter (Q1 2026) recorded $193.5 million in revenue, down 5.8% sequentially.
Historical Growth Trajectory
COLL's 5-year compound annual growth rate (CAGR) stands at +20.3%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +18.9% is below the 5-year average, signalling a growth deceleration in recent years. Collegium Pharmaceutical, Inc.'s highest annual revenue of $780.6 million was recorded in 2025, an all-time high.
Revenue by Segment
COLL's revenue is primarily driven by Belbuca (36%), Xtampza ER (32%), and Nucynta IR (19%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including AVDL (+79.9% YoY), HRMY (+20.7% YoY), and SUPN (+16.3% YoY) — COLL has underperformed the peer group in revenue growth. Compare COLL vs AVDL →
COLL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| COLLCurrent | $796M | +8.9% | +20.3% | 24.0% | |
 AVDL | $169M | +79.9% | +23.4% | -25.1% | |
 HRMY | $868M | +20.7% | +40.3% | 24.0% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% |
COLL Historical Revenue Data (2013–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $780.6M | +23.6% | $463.3M | 59.3% | $187.1M | 24.0% |
| 2024 | $631.4M | +11.4% | $377.3M | 59.8% | $169.9M | 26.9% |
| 2023 | $566.8M | +22.2% | $326.2M | 57.5% | $167.0M | 29.5% |
| 2022 | $463.9M | +67.6% | $209.5M | 45.2% | $33.3M | 7.2% |
| 2021 | $276.9M | -10.7% | $150.6M | 54.4% | $17.6M | 6.4% |
| 2020 | $310.0M | +4.5% | $179.8M | 58.0% | $56.2M | 18.1% |
| 2019 | $296.7M | +5.8% | $103.0M | 34.7% | $-23,748,000 | -8.0% |
| 2018 | $280.4M | +884.7% | $114.7M | 40.9% | $-20,685,000 | -7.4% |
| 2017 | $28.5M | +1564.3% | $25.9M | 90.9% | $-75,447,000 | -264.9% |
| 2016 | $1.7M | - | $1.5M | 87.6% | $-94,082,000 | -5498.7% |
| 2015 | $0 | - | $-171,000 | - | $-26,907,000 | - |
| 2014 | $0 | - | $0 | - | $-17,665,000 | - |
| 2013 | $0 | - | $0 | - | $-16,042,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
COLL — Frequently Asked Questions
Quick answers to the most common questions about buying COLL stock.
Is COLL's revenue growth accelerating or slowing?
COLL revenue growth is holding steady at +8.9% year-over-year. TTM revenue is $796M. The current growth rate closely tracks the 5-year CAGR of +20.3%, signalling consistent execution.
What is COLL's revenue history from 2013 to 2026?
Collegium Pharmaceutical, Inc. (COLL) revenue history spans 2013 to 2026. TTM revenue as of 2026 is $796M, growing at +8.9% YoY. The 5-year CAGR is +20.3%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is COLL's long-term revenue growth rate (CAGR)?
Collegium Pharmaceutical, Inc.'s 5-year revenue CAGR of +20.3% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +8.9% is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for COLL.
Why does COLL's quarterly revenue fluctuate?
COLL quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Collegium Pharmaceutical, Inc.'s revenue data from 2013 to 2026 shows full historical quarterly detail on this page.
How is COLL's revenue distributed by segment?
COLL reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does COLL's revenue compare to industry peers?
Collegium Pharmaceutical, Inc. (COLL) with TTM revenue of $796M and +8.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.